Theratechnologies, a biopharmaceutical company based in Montreal, experienced a significant drop in its U.S.-listed shares during premarket trading on Wednesday. The cause of this decline was the Food and Drug Administration's (FDA) rejection of Theratechnologies' application for approval of a new formulation of its HIV-related weight imbalances treatment.
The FDA has requested additional information from the company regarding immunogenicity and the chemistry, manufacturing, and controls of the F8 formulation of Egrifta. It is important to note that Egrifta is already approved in the U.S. for reducing excess abdominal fat in adults with HIV and lipodystrophy.
Theratechnologies has highlighted the advantages of the F8 formulation compared to the current formulation, marketed as Egrifta SV. These advantages include a higher concentration, allowing for a smaller volume of administration.
Following the announcement that the FDA had extended its review of the new formulation beyond the anticipated target action date, Theratechnologies' shares decreased by 7% on Tuesday. As of now, the company has stated its intention to address the FDA's requests and continue to pursue approval for the new formulation.
In premarket trading, Theratechnologies' shares experienced a further decline of 30%, falling from $1.72 to $1.20.
Overall, this rejection represents a setback for Theratechnologies as it seeks to introduce an improved treatment option for individuals with HIV-related weight imbalances.
Nokia's Fourth Quarter Results
Our Latest News
Medical Properties Trust Faces Challenges with Largest Tenant
Medical Properties Trust (MPT) faces challenges as largest tenant owes $50 million in rent. MPT takes steps to recover uncollected rent and loans.
The Future of Farming: Embracing Technology to Feed the World
Agriculture is embracing technology to feed the world, with Deere's innovations in precision farming and electric excavators at CES 2022. Learn more about these...
Sealed Air: Outlook for 2024
Sealed Air, known for Bubble Wrap, is projected to achieve mid-single-digit growth in 2024 thanks to cost-saving measures and a revival in sales volume. Other f...